Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has provided an update.
On September 9, 2025, Smith & Nephew announced a transaction involving the sale of ordinary shares by Vasant Padmanabhan, President of Research & Development ENT, who is classified as a Person Discharging Managerial Responsibilities (PDMR). The transaction, conducted outside the trading venue, involved the sale of 17,643 shares at a price of £14.25 each. This announcement is made in compliance with the UK Market Abuse Regulation, highlighting the company’s commitment to transparency in its financial dealings.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew is a global medical technology company that operates in the healthcare industry. The company specializes in the development and manufacturing of advanced medical devices, particularly in the areas of orthopedics, sports medicine, and wound management.
Average Trading Volume: 961,955
Technical Sentiment Signal: Buy
Current Market Cap: $16.69B
For detailed information about SNN stock, go to TipRanks’ Stock Analysis page.